News >

Nivolumab Sustains Survival Benefit in RCC at 3 Years

Jason Harris
Published: Monday, Nov 06, 2017

Dr Padmanee Sharma

Padmanee Sharma, MD, PhD
Nivolumab (Opdivo) reduced the risk of death by 26% compared with everolimus (Afinitor) in patients with previously treated advanced renal cell carcinoma (RCC), according to 3-year follow-up data from the phase III CheckMate-025 study.

The FDA approved nivolumab in November 2015 as a treatment for patients with metastatic renal cell carcinoma following prior antiangiogenic therapy.
Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC). Bristol-Myers Squibb. Accessed November 6, 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication